Last reviewed · How we verify
Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%
Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% is a Retinoid combination Small molecule drug developed by Galderma R&D. It is currently FDA-approved for Acne vulgaris, Photoaging and photodamaged skin. Also known as: Differin® Gel, 0.1% and Tazorac® Cream, 0.1%.
This combination product delivers two retinoid receptor agonists that normalize skin cell differentiation and reduce inflammation to treat acne and photoaging.
This combination product delivers two retinoid receptor agonists that normalize skin cell differentiation and reduce inflammation to treat acne and photoaging. Used for Acne vulgaris, Photoaging and photodamaged skin.
At a glance
| Generic name | Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% |
|---|---|
| Also known as | Differin® Gel, 0.1% and Tazorac® Cream, 0.1% |
| Sponsor | Galderma R&D |
| Drug class | Retinoid combination |
| Target | Retinoic acid receptors (RAR-α, RAR-β, RAR-γ) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Adapalene is a naphthoic acid retinoid that binds retinoic acid receptors (RARs) to promote cell turnover and reduce comedone formation. Tazarotene is a acetylenic retinoid that activates RARβ and RARγ to further enhance keratinocyte differentiation and suppress sebum production. Together, they provide synergistic anti-inflammatory and comedolytic effects.
Approved indications
- Acne vulgaris
- Photoaging and photodamaged skin
Common side effects
- Erythema
- Dryness and peeling
- Irritation
- Photosensitivity
- Burning or stinging
Key clinical trials
- Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne (PHASE4)
- Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% CI brief — competitive landscape report
- Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% updates RSS · CI watch RSS
- Galderma R&D portfolio CI
Frequently asked questions about Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%
What is Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%?
How does Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% work?
What is Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% used for?
Who makes Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%?
Is Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% also known as anything else?
What drug class is Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% in?
What development phase is Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% in?
What are the side effects of Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%?
What does Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% target?
Related
- Drug class: All Retinoid combination drugs
- Target: All drugs targeting Retinoic acid receptors (RAR-α, RAR-β, RAR-γ)
- Manufacturer: Galderma R&D — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Acne vulgaris
- Indication: Drugs for Photoaging and photodamaged skin
- Also known as: Differin® Gel, 0.1% and Tazorac® Cream, 0.1%
- Compare: Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% vs similar drugs
- Pricing: Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% cost, discount & access